Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
- Language
-
Englisch
- Identifier
-
1283187264
- Contributor
- DOI
-
10.21037/jtd.2018.09.81
- URN
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
02.05.2023, 9:12 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Smolle, Elisabeth
- Pichler, Martin
Other Objects (12)
Best of ASCO 2022: bladder cancer
Inflammation, phagocytosis and cancer: another step in the CD47 act
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
The role of microRNAs in breast cancer stem cells
The implications of the long non-coding RNA NEAT1 in non-cancerous diseases
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Multi-omics in prognosis of hepatocellular carcinoma
Best of ASCO 2022: bladder cancer
Inflammation, phagocytosis and cancer: another step in the CD47 act
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
The role of microRNAs in breast cancer stem cells
The implications of the long non-coding RNA NEAT1 in non-cancerous diseases
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Multi-omics in prognosis of hepatocellular carcinoma
Best of ASCO 2022: bladder cancer
Inflammation, phagocytosis and cancer: another step in the CD47 act
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
The role of microRNAs in breast cancer stem cells
The implications of the long non-coding RNA NEAT1 in non-cancerous diseases
RNA-binding proteins as important regulators of long non-coding RNAs in cancer